ライフサイエンスコーパス: costimulatory

1 hat replaces the Fas intracellular tail with costimulatory 4-1BB.

2 a trimeric transmembrane protein that has no costimulatory activity as a soluble molecule.

3 g cell (APC) functions, including autophagy, costimulatory activity, and the production of inflammato

4 Finally, T-cell costimulatory activity, as measured by mixed lymphocyte

5 s was accompanied by decreased expression of costimulatory and activating receptors.

6 s interaction and others between surrounding costimulatory and checkpoint molecules promote different

7 CD28 and CTLA-4 are major costimulatory and coinhibitory cell surface signaling mo

8 Costimulatory and coinhibitory receptor-ligand pairs on

9 priming with alloantigen, and the net sum of costimulatory and coinhibitory signals transmitted via l

10 Owing to different requirements in CD28 costimulatory and CTLA-4 coinhibitory signals to control

11 activates pathways shared with conventional costimulatory and cytokine receptor signaling.

12 T(fh)-GC B cell interactions by influencing costimulatory and cytokine-dependent T(fh) help to B cel

13 cal intratumoral delivery of mRNA coding for costimulatory and immune-modulating factors.

14 Costimulatory and inhibitory receptors play a key role i

15 cterized by IL-12 production and upregulated costimulatory and lymph node homing molecules on dendrit

16 2 secretion were only triggered by USSN when costimulatory anti-CD28 or phorbate esters were present,

17 In contrast, success of agonistic costimulatory antibodies has thus far been limited becau

18 Thus, booster vaccinations with agonistic costimulatory antibodies represent an ideal means to amp

19 that curtailed signaling through the B7-CD28 costimulatory axis during CD8 T cell activation limits t

20 anism by which additional activation of this costimulatory axis in tumor-associated myeloid cells is

21 coreceptor engagement, forcing the principal costimulatory axis to signal excessively.

22 Costimulatory blockade also induced IL-21R expression in

23 Finally, successful use of costimulatory blockade and B-cell depletion in the clini

24 new insights into the tolerogenic effects of costimulatory blockade and identify DC-SIGN(+) suppressi

25 emory T cells, which are less susceptible to costimulatory blockade by belatacept, or resulted from i

26 ow NK cells promote allograft survival under costimulatory blockade conditions by regulating alloreac

27 ell-mediated skin transplant rejection under costimulatory blockade conditions.

28 late alloreactive CD8+ Tcell responses under costimulatory blockade conditions.

29 In particular, costimulatory blockade did not change other previously d

30 s not impact the graft-prolonging effects of costimulatory blockade including that induced by clinica

31 Costimulatory blockade increased IL-10 in marginal zone

32 ent expression of DEPTOR in combination with costimulatory blockade induces long-term graft survival.

33 Costimulatory blockade strategies that include corticost

34 The BALB/c-mice also received costimulatory blockade through multiple-doses of anti-CD

35 terotopic cardiac allografts with or without costimulatory blockade using anti-CD154 (MR1) or CTLA4Ig

36 ignificantly prolonged allograft survival on costimulatory blockade when compared to Rag1-/-T-bet-/-

37 laying excellent immunosuppressive efficacy, costimulatory blockade with anti-CD40 monoclonal antibod

38 Costimulatory blockade with anti-CD40L monoclonal antibo

39 Costimulatory blockade-induced murine cardiac allograft

40 chanistic target of rapamycin inhibition and costimulatory blockade.

41 tion of heart transplant survival induced by costimulatory blockade.

42 resistant to the graft-prolonging effects of costimulatory blockade.

43 ted with perioperative administration of the costimulatory blocking agent CTLA4 immunoglobulin exhibi

44 , warranting future evaluation in other CD28-costimulatory CARs in an effort to improve durable antit

45 f atypical, cytotoxic CD4(+) T cells lacking costimulatory CD28 (CD4(+) CD28(null) cells) is associat

46 time, has been shown to trigger the loss of costimulatory CD28 molecules with recently reported inte

47 Blocking of costimulatory CD28/B7 and CD40/CD40L interactions is an

48 and expressed significantly higher levels of costimulatory CD40 and CD86.

49 pic challenge, indicating a novel role for a costimulatory cytokine in recall responses.

50 n-specific immunity by inducing secretion of costimulatory cytokines during T-cell activation, yet da

51 hat CD19 CAR T cells incorporating the 4-1BB costimulatory domain are more persistent than those inco

52 Differential signaling through the CAR costimulatory domain can alter the T cell metabolism, me

53 i et al. showed that a CAR containing a CD28 costimulatory domain drives progeny differentiation to r

54 etroviral CAR transduction including a 4-1BB costimulatory domain in primary T cells.

55 dings suggest that simple alterations in the costimulatory domain may enhance CAR-T cell persistence,

56 tence by changing a single amino acid in the costimulatory domain of CD28.

57 esign, combining CD19 CAR containing a 4-1BB costimulatory domain with an IGK CAR containing a CD3zet

58 This finding suggests modifications to the costimulatory domains of CAR-T cells can enable longer p

59 gle-chain spacer(6) and extracellular(7) and costimulatory domains(8), have a profound effect on CAR

60 phenomenon was independent of the choice of costimulatory domains, or the hinge/transmembrane region

61 Ts was not mitigated by the incorporation of costimulatory domains, such as 4-1BB, into the CD19-CAR.

62 ion of T-cell coinhibitory (e.g., CTLA-4) or costimulatory (e.g., 4-1BB) receptors promotes clinical

63 that the CD2-CD58 interaction has a genuine costimulatory effect on this T cell subset.

64 CD80 elongation reduced its costimulatory effect without abrogating CD28 binding.

65 We used REAP-seq to assess the costimulatory effects of a CD27 agonist on human CD8(+)

66 ing an inhibitory receptor ectodomain with a costimulatory endodomain to convert negative into positi

67 specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodomain.

68 hat merely trigger immune responses, whereas costimulatory events specify the type of reaction.

69 TIGIT and the costimulatory factor CD226 bind the common ligand CD155.

70 rometry and immunoblotting revealed that the costimulatory factor in Tc CM was glycoprotein Ib alpha

71 Exposure of NK cells to innate DC-derived costimulatory factors triggered their helper activity, d

72 Costimulatory function and cytokine modulation by CD55 w

73 this study, we analyzed T-cell coinhibitory/costimulatory genes across more than 1100 samples of the

74 observed disproportionately hypermethylated costimulatory genes and hypomethylation of immune checkp

75 renal community, implying that abatacept, a costimulatory inhibitor that targets B7-1, could be a no

76 Costimulatory interactions are required for T cell activ

77 d whether selective blockade of CD28-CD80/86 costimulatory interactions, which preserves the coinhibi

78 cell surface presentation of the immune cell costimulatory ligand CD58 while promoting maturation and

79 Costimulatory ligand expression by DCs and T cell prolif

80 The ratiometric control of costimulatory ligands (anti-CD3 and anti-CD28 antibodies

81 endogenous pathway) and the upregulation of costimulatory ligands CD70 and OX40L, thereby inducing p

82 a CTLA-4-Ig fusion protein that binds to the costimulatory ligands CD80 and CD86 and blocks their int

83 inins alpha4 and alpha5 are coinhibitory and costimulatory ligands for human and mouse CD4 T cells, r

84 ts we confirmed the deregulation of multiple costimulatory ligands on AML blasts at post-transplantat

85 here was no evidence for the upregulation of costimulatory ligands or cytokine secretion.

86 nes that were engineered to express CD1d and costimulatory ligands.

87 IL-6) as well as decreased MHC class II and costimulatory marker (CD80/86) expression.

88 B cells lacked the ability to upregulate the costimulatory marker CD40, suggesting IDO2 acts at the T

89 DC expression of the costimulatory marker CD86 was significantly reduced in a

90 nization of maximum antigen presentation and costimulatory marker expression.

91 erived dendritic cells (moDC) and lower moDC costimulatory maturation.

92 cells (tAPCs) by inducing coexpression of a costimulatory molecule (4-1BBL) and immunostimulatory cy

93 formatics analysis identified that inducible costimulatory molecule (ICOS)(+) T(FH) cells and other I

94 Here, we have shown that expression of the costimulatory molecule and microbial sensor SLAMF1 (also

95 ant target on malignant cells and the proper costimulatory molecule are essential for CAR T cell effi

96 uence TCR repertoire diversity by modulating costimulatory molecule availability.

97 rom patients exhibited downregulation of the costimulatory molecule CD226, which competes with TIGIT

98 The costimulatory molecule CD40 enhances immunity through se

99 The costimulatory molecule CD40 is a major driver of atheros

100 duced the expression of MHC class II and the costimulatory molecule CD40 on the surface of the cells.

101 ized that the simultaneous expression of the costimulatory molecule CD40L (CD154) by the ALVAC-HIV ve

102 mation of memory T cells, which requires the costimulatory molecule CD70 on antigen-presenting cells,

103 mice with HSV-1 suppressed expression of the costimulatory molecule CD80 but not CD86 in the cornea.

104 It downregulates the expression of the costimulatory molecule CD80 but not CD86 on resident den

105 The costimulatory molecule CD80 is an early marker for immun

106 -dependent downregulation of the host T cell costimulatory molecule CD80.

107 ells results in heightened expression of the costimulatory molecule CD86 and the lymph node homing mo

108 fed mice also enhanced the expression of the costimulatory molecule CD86 on cultured MCs, whereas OVA

109 , we provide evidence that hBD-3 induces the costimulatory molecule CD86 on primary human monocytes b

110 node, as well as increased expression of the costimulatory molecule CD86.

111 Activation of the immune costimulatory molecule cluster of differentiation 40 (CD

112 CD48 (SLAMF2) is an adhesion and costimulatory molecule constitutively expressed on hemat

113 CD300c works as a costimulatory molecule during IgE-mediated basophil acti

114 tation in TNFRSF9 gene coding CD137/4-1BB, a costimulatory molecule expressed by antigen-specific act

115 ncreased Ag uptake and increased PRR-induced costimulatory molecule expression and chemokine and cyto

116 LR9 agonists, as well as TLR agonist-induced costimulatory molecule expression and TNF-a (but not IL-

117 ass-switched memory B cells and intermediate costimulatory molecule expression between naive and clas

118 Notably, related to the high-level costimulatory molecule expression induced by lymphocytic

119 ng technology, and measurement of MHC II and costimulatory molecule expression on DCs by using flow c

120 he presence of cis-UCA significantly reduced costimulatory molecule expression on monocyte-derived de

121 nsion with diminished cytokine but increased costimulatory molecule expression, and capacity for prof

122 red the release of TH1-polarizing cytokines, costimulatory molecule expression, and T-cell activation

123 ough alum-adjuvanted vaccines induced modest costimulatory molecule expression, limited TH-polarizing

124 , whereas cDCs are most efficient in MHC and costimulatory molecule expression.

125 ell-specific molecule that serves as a major costimulatory molecule for amplifying B-cell receptor (B

126 OX40 is a costimulatory molecule from the TNFR family.

127 Here, we show that the host CD80 T cell costimulatory molecule functions similarly to LAT and ca

128 Mechanistically, the costimulatory molecule ICOS activated mTORC1 and mTORC2

129 Purpose CD27, a costimulatory molecule on T cells, induces intracellular

130 nodes and PDK1-dependent soluble Ag uptake, costimulatory molecule upregulation, and secretion of Th

131 esponses, or myeloid antigen-presenting cell costimulatory molecule upregulation.

132 oid-induced TNFR-related protein (GITR) is a costimulatory molecule with diverse effects on effector

133 , the authors used a second generation 4-1BB costimulatory-molecule-based chimeric antigen receptor (

134 e (HLA-DR(+), CD38(+), Bcl-2(lo)), expressed costimulatory molecules (CD28, CD27, ICOS), and had high

135 ng in a sharp inhibition of MHC class II and costimulatory molecules (CD40, CD86) expression as well

136 its) and enhanced expression of MHC-E and of costimulatory molecules (CD70 and CD80, but not CD86).

137 se to stimulation, fibroblasts expressed the costimulatory molecules 4-1BBL, OX-40L, and CD70, all of

138 ized mice exhibited heightened expression of costimulatory molecules and attenuated expression of coi

139 s, as indicated by defective upregulation of costimulatory molecules and CD83, as well as reduced sec

140 nti-BAFF treatment on B cells, expression of costimulatory molecules and cytokines, germinal centers

141 3E KO mice displayed increased expression of costimulatory molecules and IL-12p40 production followin

142 Ex vivo, reduced expression of costimulatory molecules and impaired M1 polarization wer

143 rophils up-regulated expression of MHCII and costimulatory molecules and increased T cell activation.

144 to a reduced activation profile with reduced costimulatory molecules and proinflammatory cytokine pro

145 ation of key DC mRNAs, like those coding for costimulatory molecules and proinflammatory cytokines, w

146 y unusual phenotype by which DCs up-regulate costimulatory molecules and secretion of chemokines, but

147 a process involving up-regulation of MHC and costimulatory molecules and secretion of proinflammatory

148 nd porcine APC, with increased expression of costimulatory molecules and secretion of TNF and IL-1bet

149 Nano-11 induced increased expression of costimulatory molecules and the secretion of IL-1beta an

150 erms of TCR signaling, use of coreceptor and costimulatory molecules and their development.

151 t2(-/-) cDCs displayed reduced expression of costimulatory molecules and type I IFN-stimulated genes.

152 eightened cell surface expression of MHC and costimulatory molecules as well as cytokine production.

153 rotein level, moLCs showed low expression of costimulatory molecules but prominent expression of C-ty

154 d cytokine release and surface expression of costimulatory molecules by untreated or inhibitor-treate

155 F2 deficiency enhanced surface expression of costimulatory molecules CD40 and CD86 in DCs and promote

156 nger RNA expression of interleukin-6 and the costimulatory molecules CD40 and inducible T cell costim

157 ession of the maturation marker CD83 and the costimulatory molecules CD40, CD80, and CD86, decreased

158 leukocyte antigen antigen D related and the costimulatory molecules CD40, CD80, and CD86.

159 -1, and Blimp-1, and decreased expression of costimulatory molecules CD40L, CD28, and ICOS on the T c

160 esentation and T cell priming, including the costimulatory molecules CD80, CD86, and CD40.

161 h was explained by increased upregulation of costimulatory molecules CD86 and MHC class II on moDCs i

162 efects in the expression of MHC class II and costimulatory molecules corresponded with a reduced capa

163 ng between numerous adhesion, signaling, and costimulatory molecules defines both the topographical a

164 C maturation markers such as MHC class I and costimulatory molecules following infection with the clo

165 Our study showed that most costimulatory molecules have a low capacity to activate

166 proliferation and expression of effector and costimulatory molecules in a tumor antigen-dependent man

167 proinflammatory cytokines and expression of costimulatory molecules in mouse macrophages.

168 fficacy in multiple cancers, but the role of costimulatory molecules in this T cell rescue remains el

169 in activates DCs to induce the expression of costimulatory molecules in vitro.

170 pecific expression of several chemokines and costimulatory molecules indicated in thymocyte developme

171 B cells leads to aberrant expression of key costimulatory molecules involved in proinflammatory T ce

172 The involvement of costimulatory molecules is potent, and a mechanistic und

173 mphoma cell line and prevent upregulation of costimulatory molecules of LPS-stimulated human dendriti

174 derived in part from enhanced expression of costimulatory molecules on B cells, marked increase of T

175 g with the TCR; signal 2, the interaction of costimulatory molecules on T cells and APCs; and signal

176 Agonist antibodies (Ab) directed against costimulatory molecules on the surface of antigen-primed

177 viral genomes or to differences in levels of costimulatory molecules required for this interaction.

178 int blockade therapy targets T cell-negative costimulatory molecules such as cytotoxic T lymphocyte a

179 ibitory receptor, but also expressed several costimulatory molecules such as ICOS and CD28.

180 flow cytometry; expression of cytokines and costimulatory molecules was measured by quantitative pol

181 cells (BMDCs) compared to WT BMDCs, although costimulatory molecules were upregulated in both types o

182 hibit modestly reduced surface expression of costimulatory molecules whose expression is similarly de

183 sentation, (ii) repressing T cell-activating costimulatory molecules, and (iii) inducing ligands that

184 g recognition through the TCR, engagement of costimulatory molecules, and cytokines.

185 ogressive differentiation, downregulation of costimulatory molecules, and elevated CXCR3 expression a

186 e, they have low expression of MHC class II, costimulatory molecules, and low arginase1 expression.

187 ression of functional MHC-peptide complexes, costimulatory molecules, and other components that inter

188 the expression of dendritic cells (DCs) and costimulatory molecules, B cells, T cells, TH2-related c

189 le, we addressed the role of cDC1s and their costimulatory molecules, CD40, CD70, and CD80/CD86, in e

190 ein structurally related to the B7 family of costimulatory molecules, is necessary but insufficient f

191 Costimulatory molecules, such as the programmed death li

192 s by increasing the expression of HLA-DR and costimulatory molecules, which resulted in improved indu

193 including increased expression of lymphocyte costimulatory molecules.

194 and large airways, which express HLA-DR and costimulatory molecules.

195 not due to diminished upregulation of MHC or costimulatory molecules.

196 creased expression of both the CD80 and CD86 costimulatory molecules.

197 rive their proliferation despite lacking key costimulatory molecules.

198 clinical targeting of 4-1BB or likely other costimulatory molecules.

199 w focuses on the combination of cytokine and costimulatory networks at the T-cell surface that culmin

200 s and events occurring downstream of TCR and costimulatory or coinhibitory receptor engagement.

201 ation rather than differential expression of costimulatory or inhibitory molecules.

202 Importantly, blocking the costimulatory OX40L (OX40 ligand)-OX40 axis reduced Tfh-

203 In addition, the CD28-CD80/86 costimulatory pathway appeared to be sufficiently blocke

204 ly identify the CD58/CD2 axis as the primary costimulatory pathway for CD8 T cells that lack CD28.

205 Surprisingly, this costimulatory pathway had minimal effect on early T cell

206 nti-CD40 antibodies targeting the CD40/CD154 costimulatory pathway has just completed a phase II tria

207 Here, we demonstrate that the CD28/B7 costimulatory pathway is essential for effective PD-1 th

208 The CD27-CD70 costimulatory pathway is essential for the full activati

209 , our results demonstrate that the CD27-CD70 costimulatory pathway regulates the differentiation prog

210 The CD27/CD70 costimulatory pathway was shown to be critical for T cel

211 to be a promising blocker of the CD40-CD154 costimulatory pathway with potential use in transplantat

212 Belatacept, an inhibitor of the CD28-CD80/86 costimulatory pathway, allows for calcineurin-inhibitor

213 ally and uniquely dictate the utilization of costimulatory pathways allowing shaping of effector and

214 In addition to TCR signaling, costimulatory pathways are involved in T cell activation

215 rate that immunotherapies that target T cell costimulatory pathways block the rejection of xenogeneic

216 One of the best-characterized costimulatory pathways includes the Ig superfamily membe

217 D8(+) T cells because of redundancy with the costimulatory pathways induced by TNF receptor family me

218 that have addressed how major inhibitory and costimulatory pathways play a role in regulating immune

219 inactivating CD28 signaling, suggesting that costimulatory pathways play key roles in regulating effe

220 innate-like T cells by providing alternative costimulatory pathways that gain relevance in chronic in

221 Downstream of costimulatory pathways, complexes of transcription facto

222 ature pDCs in the lymph node, with a reduced costimulatory potential and enhanced infiltration of pDC

223 include selective CD28 blockade to block the costimulatory potential of CD28 while exploiting the coi

224 mental to T-cell memory, we incorporated its costimulatory properties by coexpressing CAR with a memb

225 The costimulatory properties of second-generation chimeric a

226 rface molecule CD83, which was shown to have costimulatory properties, is targeted by herpes simplex

227 possibility of small-molecule inhibition of costimulatory protein-protein interactions, establish th

228 Of relevance the costimulatory proteins CD80/CD86, signals needed for reg

229 While H. pylori increased the expression of costimulatory proteins on DCs, IL-21 reduced the express

230 Activation of costimulatory receptor CD137 with mAb (4-1BB) exerted st

231 57(+) CD4 T cells express high levels of the costimulatory receptor CD2 and that CD2/LFA-3 costimulat

232 tors and was diminished upon blockade of the costimulatory receptor CD28 and deficiency of the signal

233 nd nonoverlapping roles for the noninducible costimulatory receptor CD28 and the inflammatory cytokin

234 he T cell antigen receptor and the principal costimulatory receptor CD28.

235 ctor receptor superfamily 9) is an inducible costimulatory receptor expressed on activated T and natu

236 alpha and gp130, enhancing expression of the costimulatory receptor ICOS and promoting expression of

237 T cells stimulated with an agonist of either costimulatory receptor individually.

238 However, it is currently unknown how this costimulatory receptor influences CD4(+) effector T (Tef

239 lethality by blocking the superantigen-host costimulatory receptor interaction.

240 GBR 830 is a humanized mAb against OX40, a costimulatory receptor on activated T cells.

241 CD40 is a costimulatory receptor on APCs that is critical for the

242 erfamily of cell surface proteins, acts as a costimulatory receptor on T cells, natural killer cells,

243 molecule in immunosuppression, and CD80 is a costimulatory receptor promoting T cell activation.

244 cyte activation molecule 6 expression, a TCR costimulatory receptor required for NKT cell development

245 GITR is a T-cell costimulatory receptor that enhances cellular and humora

246 t has been identified as an important T cell costimulatory receptor, and patients deficient in CD46 o

247 CD28 acts as the primary T cell costimulatory receptor, but there are numerous additiona

248 tail replaced by the signaling domain of the costimulatory receptor, CD28.

249 el of cell-surface CD28, an important T cell costimulatory receptor.

250 stimulation of the TCR in conjunction with a costimulatory receptor.

251 on gammadeltaT cells that expressed chimeric costimulatory receptors (CCRs) lacking CD3zeta but conta

252 ls exhibited significantly reduced levels of costimulatory receptors (inducible T-cell costimulator,

253 Combined agonist stimulation of the TNFR costimulatory receptors 4-1BB (CD137) and OX40(CD134) ha

254 activation requires interaction between the costimulatory receptors B7-2 and CD28.

255 Whereas costimulatory receptors such as ICOS are accepted as bei

256 for the clustering of lipid rafts, TCR, and costimulatory receptors toward the T:APC interface.

257 transmitting intracellular signals from Ag, costimulatory receptors, and cytokine receptors to contr

258 ally requires engagement of both the TCR and costimulatory receptors, such as CD28.

259 a and PI3Kdelta are activated by the TCR and costimulatory receptors, whereas PI3Kgamma is activated

260 considered to be members of the B7 family of costimulatory receptors, which includes B7.1 (CD80), B7.

261 T cell receptor alone or in combination with costimulatory receptors.

262 We hypothesized that blockade of the T cell costimulatory signal by the CTLA4-Ig synthetic protein (

263 A costimulatory signal from the tumor necrosis factor rece

264 The precise costimulatory signal requirements for proper TFR cell di

265 ellin, a TLR5 ligand (TLR5L), can engender a costimulatory signal that augments antitumor activity.

266 4-1BB provides a costimulatory signal that enhances CD8(+) T-cell surviva

267 T-cell coregulatory receptor that provides a costimulatory signal to T cells during antigen-mediated

268 The CD27-CD70 pathway is known to provide a costimulatory signal, with CD70 expressed on APCs and CD

269 7-H3 is responsible for providing a negative costimulatory signal.

270 to cytotoxic effector cells upon therapeutic costimulatory signaling and restore antitumor immunity.

271 yte antigen 4-Ig), a fusion protein blocking costimulatory signaling between antigen-presenting cells

272 hage migration inhibitory factor and provide costimulatory signaling during naive CD4(+) T cell primi

273 new transcriptional targets of CD28-mediated costimulatory signaling in human regulatory T and Tfh ce

274 y targeted activation of multiple innate and costimulatory signaling pathways, such as CD40 or TLRs.

275 Understanding the costimulatory signaling that enhances the activity of cy

276 ll proliferation, thereby linking changes in costimulatory signaling to impaired activation, prolifer

277 the agonism of the 41BB-41BBL axis enhanced costimulatory signals and effector functions among APC a

278 her TLR ligands have the capacity to provide costimulatory signals and enhance Ag-driven T cell activ

279 nate immune cells that are a major source of costimulatory signals and inflammatory mediators in the

280 Concurrent costimulatory signals at the APC-T-cell interface (eg, C

281 The activation of 41BB costimulatory signals by agonistic Abs enhances the expa

282 TCR signaling in the absence of costimulatory signals can lead to an abortive attempt at

283 ha-4-1BB antibody is known to provide strong costimulatory signals for augmenting and diversifying T-

284 BB agonistic Abs are supported by additional costimulatory signals from tumor-associated myeloid cell

285 4-1BB (CD137, TNFRSF9) mediates costimulatory signals important for activation and persi

286 Blocking CD40-CD40L costimulatory signals induces transplantation tolerance.

287 Survival or costimulatory signals rescue B cells from this fate, but

288 1A (TL1A) is expressed on APCs and provides costimulatory signals to activated lymphocytes that bear

289 CD27 signaling provides costimulatory signals to cytotoxic T cells but also incr

290 DC maturation is necessary to provide costimulatory signals to T cells, but while DC maturatio

291 These DNA extrusions convey autocrine costimulatory signals to T lymphocytes and can be detect

292 APC are the key providers of TNF superfamily costimulatory signals, a signal we refer to as signal 4

293 gonistic CD3 and CD28 Abs, mimicking TCR and costimulatory signals, coordinately induces 4-1BB and cR

294 Thus, rather than providing costimulatory signals, the CD27-CD70 axis may represent

295 a primary recognition signal and additional costimulatory signals.

296 ation through a combination of integrins and costimulatory signals.

297 ic CD8(+) T cells is slightly redundant with costimulatory signals.

298 tor function following initial activation by costimulatory signals.

299 ses by providing either positive or negative costimulatory signals.

300 Tregs express several costimulatory TNF receptor family members that activate